Abstracts tagged "interferons and monocytes"

Abstract Number: 1026 • 2018 ACR/ARHP Annual Meeting
Autoinflammatory Diseases, Particularly SAVI and Candle, Are Driven By Chronically Active Type I Interferons
Bernadette Marrero¹, Katherine R. Calvo², Yin Liu³, Angelique Biancotto⁴, Yan Huang¹ and Raphaela Goldbach-Mansky¹, ¹Translational Autoinflammatory Disease Section (TADS), Laboratory of Clinical Investigation and Microbiology (LCIM), NIAID/NIH, Bethesda, MD, ²Department of Laboratory Medicine, Hematology Section, National Institutes of Health Clinical Center, Bethesda, MD, ³Scientific Review Branch, NIAMS/NIH, Bethesda, MD, ⁴Center for Human Immunology Autoimmunity and Inflammation (CHI), NIAID, NIH, Bethesda, MD
Background/Purpose: STING Associated Vasculopathy with onset in Infancy (SAVI)is caused by gain-of-function mutations in TMEM173/STING and Chronic Atypical Neutrophilic Dermatosis with Lipodystrophy and Elevated Temperature…
Abstract Number: 528 • 2012 ACR/ARHP Annual Meeting
Mxa As a Biomarker for Systemic Interferon Type I Activation in Primary Sjögren′s Syndrome
Naomi I. Maria¹, Zana Brkic¹, Matti Waris², Cornelia G. van Helden-Meeuwsen¹, Kim Heezen¹, Joop P. van de Merwe¹, Paul L. van Daele³, Virgil A. Dalm³, Hemmo A. Drexhage³ and Marjan A. Versnel³, ¹Immunology, Erasmus Medical Center, Rotterdam, Netherlands, ²Department of Virology, University of Turku, Turku, Finland, ³Erasmus Medical Center, Immunology, Rotterdam, Netherlands
Background/Purpose: To establish an easy and practical assay for detection of systemic Interferon (IFN) type I activation in primary Sjögren's syndrome (pSS). The monocyte IFN…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].